Latest Research And Development News

Empire Energy Group is advancing its Carpentaria-5H well hydraulic stimulation scheduled for June 2025, alongside preparations for the Carpentaria Gas Plant construction, aiming to commence gas sales from EP187 by late 2025 or early 2026.

Avecho Biotechnology has inked a decade-long exclusive licensing agreement with Sandoz for its pharmaceutical-grade cannabidiol capsule targeting insomnia in Australia, backed by a US$3 million upfront payment and promising milestone and royalty streams.

Blue Energy has resolved a significant legal hurdle by securing an amended Environmental Authority for its Sapphire asset, enabling progression of the Petroleum Lease 1034 and continued pilot production testing despite operational interruptions.

Acrux Limited reports strong momentum from recent topical pharmaceutical launches, driving a significant uptick in profit share income expected in the coming quarter. The company also secured nearly $4 million through a placement and share purchase plan, alongside a $1.73 million R&D-backed loan.

Linius Technologies embarks on a strategic transformation under CEO Ben Taverner, focusing on operational restructuring, AI-enhanced SaaS products, and market expansion beyond sports to achieve breakeven by June 2026.

Pure Hydrogen Corporation has marked significant progress in its clean energy transition, delivering Australia's first hydrogen fuel cell garbage truck and securing multi-million dollar contracts with industry leaders TOLL Transport and Heidelberg Materials.

Argent BioPharma reports significant operational savings through manufacturing outsourcing, encouraging Phase IIb results for CimetrA®, and key regulatory approvals for cannabinoid therapies in Germany.

Patrys Limited advances its PAT-DX3 therapy development for inflammatory diseases while navigating cash flow challenges and pursuing partnerships to sustain operations.

Red Metal Limited's March 2025 quarterly report reveals robust progress across its rare earth and base metals projects, underpinned by promising drilling results and supportive government funding.

Starpharma reports steady progress in its DEP® drug development programs, launches new marketing campaigns in key regions, and maintains a strong cash position of $17.2 million as it refines clinical strategies and partnerships.

Alterity Therapeutics reports compelling Phase 2 clinical trial results for ATH434 in Multiple System Atrophy, alongside a significant capital raise strengthening its financial position for upcoming regulatory milestones.

Microba Life Sciences reports robust growth in microbiome diagnostic testing across Australia and the UK, while advancing US market entry plans and transitioning its Therapeutics business to a partnering model.